May 9, 2025 06:57 AM EDT

Corvus' early-phase atopic dermatitis data prompt stock rally

Max Gelman

Senior Editor

Corvus Pharmaceuticals reported new Phase 1 data in atopic dermatitis that sent its stock price $CRVS up by as much as …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

ENDPOINTS CAREERS

VP, Clinical Development / CMO / CDO‬ ‭ (Stealth Portfolio Company)

Autonomy Bio Inc.

San Francisco, CA 94107, USA

view job offer post your job now

TRENDING NOW

Lilly shuffles key executive positions; Mikael Dolsten takes another post-Pfizer assignment

Revolution’s KRAS drugs appear competitive in several lung cancer settings

AI biotech Insilico Medicine goes for third attempt at Hong Kong IPO

Sanofi scraps IGM deal; Lilly to pay $250M to continue work with Purdue University

'Find a way, or make one': How two scientists hope to revitalize CRISPR's rare disease crisis

sponsored

In one of the riskiest industries — Biotech — a surefire way to neutralize some of that risk emerges